Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/22
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022GlobeNewsWire • 10/21/22
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in AdultsGlobeNewsWire • 10/20/22
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022GlobeNewsWire • 10/10/22
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep ApneaGlobeNewsWire • 10/03/22
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A MeetingGlobeNewsWire • 09/29/22
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare ConferenceGlobeNewsWire • 09/21/22